Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations

Reuters
2025/11/06
Healthcare tech firm <a href="https://laohu8.com/S/CCLD">CareCloud</a>'s Q3 revenue up 9%, beats expectations

Overview

  • CareCloud Q3 revenue rises 9% yr/yr, beating analyst expectations

  • Company raises full-year 2025 revenue guidance to $117-$119 mln

  • CareCloud completes Medsphere acquisition, accelerates AI initiatives

Outlook

  • CareCloud raises full-year 2025 revenue guidance to $117-$119 mln

  • Company expects full-year 2025 adjusted EBITDA of $26-$28 mln

  • CareCloud projects full-year 2025 EPS of $0.10-$0.13

Result Drivers

  • ACQUISITIONS - Completion of Medsphere acquisition and others contributed to revenue growth and market expansion

  • AI INITIATIVES - AI integration into platforms enhanced performance and opened new sales opportunities

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$31.10 mln

$28.62 mln (3 Analysts)

Q3 EPS

$0.04

Q3 Adjusted Net Income

$4.40 mln

Q3 Adjusted EBITDA

$7.70 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for CareCloud Inc is $6.00, about 50.8% above its November 5 closing price of $2.95

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNXbSFQC5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10